Federal Judge Clears Way for Jury Trial in Elon Musk’s Fraud Lawsuit Against OpenAI and Microsoft 
Zhipu AI Launches GLM-Image Model Trained on Huawei Chips, Boosting China’s AI Self-Reliance Drive 
China’s AI Models Narrow the Gap With the West, Says Google DeepMind CEO 
Boeing Reaches Tentative Settlement With Canadian Victim’s Family in 737 MAX Crash Lawsuits 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings 
Elon Musk Seeks $134 Billion in Lawsuit Against OpenAI and Microsoft Over Alleged Wrongful Gains 
xAI Restricts Grok Image Editing After Sexualized AI Images Trigger Global Scrutiny 
BYD Shares Rise in Hong Kong on Reports of Battery Supply Talks With Ford 
One Percent Rule Checklist For Safer Forex Trading Risk 
Walmart International CEO Kathryn McLay to Step Down After Two and a Half Years 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
Publishers Seek to Join Lawsuit Against Google Over Alleged AI Copyright Infringement 
Jamie Dimon Signals Possible Five More Years as JPMorgan CEO Amid Ongoing Succession Speculation 
Chevron Set to Expand Venezuela Operations as U.S. Signals Shift on Oil Sanctions 
NEW YORK, April 13, 2017 -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical stage biopharmaceutical company focused on the development of innovative cancer therapies, today announced that it will host an operational update conference call with the investment community on Friday, April 28, 2017, at 8:30 a.m. Eastern Time.
The conference call will feature remarks by Dr. Lan Huang, Ph.D., Chairman and CEO, and Richard Brand, CFO. The dial-in numbers for the conference call are +1.877.451.6152 (U.S. Toll Free) or +1.201.389.0879 (International). Please ask the operator to join you into the BeyondSpring Call.
A live webcast of the conference call will be available online which can be accessed through the Investor Relations section of BeyondSpring’s website, http://ir.beyondspringpharma.com. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast.
For interested individuals unable to join the conference call, a replay of the call will be available through May 12, 2017, at +1.844.512.2921 (U.S. Toll Free) or +1.412.317.6671 (International). Participants must use the following code to access the replay of the call: 13659965. Also, a replay of the webcast will remain available on http://ir.beyondspringpharma.com for 30 days following the call.
The Company also plans to issue an operational update press release on Friday, April 28th before the U.S. markets open, which will include its financial results for the year ended December 31, 2016.
About BeyondSpring
BeyondSpring is a global clinical stage biopharmaceutical company developing innovative immuno-oncology cancer therapies with a robust pipeline from internal development and from collaboration with Fred Hutchinson Cancer Research Center and University of Washington. BeyondSpring is advancing its lead asset, Plinabulin, into a Phase 3 clinical trial as a direct anticancer agent in non-small cell lung cancer and a Phase 2/3 clinical trial in the prevention of chemotherapy-induced Neutropenia. BeyondSpring has a seasoned management team with many years of experience bringing drugs to market.
Investor Relations: Garth Russell / Allison Soss KCSA Strategic Communications P: +1-212-682-6300 [email protected] / [email protected] Media Relations: Caitlin Kasunich / Amy Singh KCSA Strategic Communications 212.896.1241 / 212.896.1207 [email protected] / [email protected]
